Abstract
The potential exposure to ribavirin aerosol in the environment was assessed in nurses caring for infants and children with severe lower respiratory tract infections due to respiratory syncytial virus. Ribavirin aerosol was administered via a ventilator, oxygen tent, or oxygen hood. Participants worked directly with infants receiving ribavirin for 20.0 to 35.0 h over a 3-day period. No toxic or adverse effects of ribavirin aerosol were observed in any of the 19 nurses studied, and ribavirin was not detected in erythrocytes, plasma, or urine collected after the potential exposure period.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Fernandez H., Banks G., Smith R. Ribavirin: a clinical overview. Eur J Epidemiol. 1986 Mar;2(1):1–14. doi: 10.1007/BF00152711. [DOI] [PubMed] [Google Scholar]
- Gilbert B. E., Wilson S. Z., Knight V., Couch R. B., Quarles J. M., Dure L., Hayes N., Willis G. Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84. Antimicrob Agents Chemother. 1985 Mar;27(3):309–313. doi: 10.1128/aac.27.3.309. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hall C. B., McBride J. T., Gala C. L., Hildreth S. W., Schnabel K. C. Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease. JAMA. 1985 Dec 6;254(21):3047–3051. [PubMed] [Google Scholar]
- Hanley J. A., Lippman-Hand A. If nothing goes wrong, is everything all right? Interpreting zero numerators. JAMA. 1983 Apr 1;249(13):1743–1745. [PubMed] [Google Scholar]
- Rodriguez W. J., Kim H. W., Brandt C. D., Fink R. J., Getson P. R., Arrobio J., Murphy T. M., McCarthy V., Parrott R. H. Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease. Pediatr Infect Dis J. 1987 Feb;6(2):159–163. doi: 10.1097/00006454-198702000-00004. [DOI] [PubMed] [Google Scholar]